Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES

    METABOLISM QUALIFIED CRYOPRESERVED HUMAN HEPATOCYTES

    Sol. FDASSN132690Sources SoughtROCKVILLE, MD
    Closed
    STATUS
    Closed
    closed May 8, 2026
    POSTED
    May 4, 2026
    Publication date
    NAICS CODE
    325414
    Primary industry classification
    PSC CODE
    6505
    Product & service classification

    AI Summary

    The FDA is seeking information from small businesses capable of providing metabolism-qualified cryopreserved human hepatocytes and associated materials for regulatory science research. The opportunity includes supplying 24 vials from four different female donors, along with necessary protocols and media. Responses will assist in determining acquisition methods and potential set-asides.

    Contract details

    Solicitation No.
    FDASSN132690
    Notice Type
    Sources Sought
    Posted Date
    May 4, 2026
    Response Deadline
    May 8, 2026
    NAICS Code
    325414AI guide
    PSC / Class Code
    6505
    Primary Contact
    Shavone Jeter
    State
    MD
    ZIP Code
    20857
    AI Product/Service
    both

    Description

    This is a Food and Drug Administration (FDA) Small Business Sources Sought Notice for Commercial Supplies. This is NOT a solicitation for proposals, proposal abstracts, or quotations.

    The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition is 325414; Biological Product (except Diagnostic) Manufacturing, with a small business standard size of 1,250 employees. The Product Service Code (PSC) is 6505: Drugs and Biologicals.

    Responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code is still encouraged to submit a Capabilities Statement.

    **QUESTIONS WILL NOT BE ENTERTAINED AS A RESULT OF THIS NOTICE**

    BACKGROUND

    The United States Food and Drug Administration (FDA) has a mission to protect public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. In addition, FDA is responsible for facilitating innovations that make medicines more effective, safer, and more affordable. To accomplish these goals, FDA has stimulated advancement of regulatory science, which is defined as “the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA regulated products.” FDA’s vision is to facilitate the integration of new science into the process of evaluating the safety and efficacy of proposed and marketed products and to close the gap between scientific innovation and this process of drug review. To achieve this vision, we perform mission-critical research to develop and evaluate tools, standards, and approaches to assess the safety, efficacy, quality, and performance of drugs.

    The Division of Applied Regulatory Science (DARS) is conducting a research project to examine the effect of female sex hormones on in vitro drug metabolism. DARS operates several labs that provide mission- critical research supporting review questions, translational science, and emerging public health issues for Center for Drug Evaluation and Research (CDER) and FDA. We develop and evaluate novel tools, standards, and approaches that increase the regulatory efficiency of developing and reviewing safe and effective CDER products. These operational supplies are essential for the continuance of these projects across our labs, and for continued preparedness to be able to respond to emergent public health issues when called upon.

    OBJECTIVE

    The supplier is to provide protocol(s) for the thawing, plating and culturing the hepatocytes. This is to include the media composition and source for all these stages for the hepatocytes. The supplier will provide up to a total of 24 vials of cryopreserved human hepatocytes from 4 different female donors. Additionally, thawing and incubation media is required for the hepatocyte cultures.

    PROJECT REQUIREMENTS

    The U.S. Food and Drug Administration (FDA), Office of Clinical Pharmacology (OCP), Division of Applied Regulatory Science (DARS), requires metabolism-qualified cryopreserved human hepatocytes and associated materials to support mission-critical regulatory science research.

    TECHNICAL REQUIREMENT SUMMARY

    Respondents shall demonstrate the ability to provide cryopreserved human hepatocytes that meet the following requirements:

    DONOR REQUIREMENTS

    • Four (4) single-donor lots (not pooled)
    • Donor demographics:
      • One (1) donor aged 20–35 years
      • Three (3) donors aged 54–70 years
    • Donors must be:
      • Of U.S. origin
      • Negative for HIV and Hepatitis B/C
      • With available CMV and EBV test results

    CELL QUALITY REQUIREMENTS

    • Minimum 5 million viable hepatocytes per vial
    • Minimum ≥85% viability post-thaw
    • Must be metabolism-qualified, including:
      • CYP1A2
      • CYP2B6
      • CYP2C9
      • CYP2C19
      • CYP2D6
      • CYP3A4
    • Must be:
      • Plateable in multi-well plates (12-well format)
      • Functional for 4–5 days post-plating

    DOCUMENTATION REQUIREMENTS

    Each donor lot must include:

    • Certificate of Analysis (CoA) or equivalent
    • Donor information (as available):
      • Age, sex, race/ethnicity
      • Cause of death
      • Substance use history
      • Liver-related medical conditions
    • Metabolism activity data
    • Biosafety information

    DELIVERABLES

    The contractor shall provide:

    • 24 total vials (6 vials per donor lot × 4 donors)
    • Associated materials, including:
      • Thawing media
      • Incubation/culture media
      • Antibiotic mix (if applicable)
    • Cryogenic shipping container (e.g., cryoshipper)

    PROTOCOL REQUIREMENTS

    The contractor shall provide protocol documentation (PDF format) prior to shipment, including:

    • Thawing procedures
    • Plating procedures
    • Culture conditions
    • Media composition and sourcing

    SHIPPING & DELIVERY REQUIREMENTS

    • Shipment must maintain product integrity using:
      • Dry ice or liquid nitrogen
    • Delivery must occur:
      • Within 7 days of award
      • Monday–Friday, 9:00 AM – 3:00 PM (excluding federal holidays)
    • Delivery location:

    U.S. Food and Drug Administration
    10903 New Hampshire Ave
    Silver Spring, MD 20993

    • Delivery must be coordinated in advance with the Government POC

    PERIOD OF PERFORMANCE

    The anticipated period of performance is six (6) months from date of award.

    CAPABILITIES AND TECHNICAL EXPERIENCE

    Provide a capability statement describing how your company would be able to meet the requirements.

    BUSINESS STATUS

    Please provide your business size status (e.g., small business, 8(a), HUBZone, etc.) and SAM.gov Unique Entity Identifier (UEI) number.

    DISCLAIMER AND IMPORTANT NOTES

    This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work.

    Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation.

    Responses to the sources sought shall be no longer than 10 pages.

    Key dates

    1. May 4, 2026Posted Date
    2. May 8, 2026Proposals / Responses Due

    AI search tags

    Frequently asked questions

    METABOLISM QUALIFIED CRYOPRESERVED HUMAN HEPATOCYTES is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.